OWC Pharma’s Dr. Rozenblat Eyes Huge Potential for Psoriasis Cream


Ryan Allway

July 19th, 2017

News, Top Story


The cannabis industry is projected to exceed $50 billion by 2026 thanks to the legalization of recreational marijuana, according to Cowen & Co., but investors shouldn’t lose focus on the medical side of the industry. Researchers have been intensifying their efforts to understand the impact of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) on a wide array of medical conditions that haven’t been studied for years under prohibition.

CFN Media’s Mike Elliott recently sat down with Dr. Sharon Rozenblat to discuss OWC Pharmaceuticals Research Corp.’s (OTCQB: OWCP) unique psoriasis skin cream and its potential within a rapidly growing multi-billion dollar market. Dr. Rozenblat is an Advisory Board Member for OWC and is largely responsible for the development of the active cannabinoid topical cream.

 

OWC Pharma’s Approach

OWC Pharmaceutical Research is an Israel-based research company focused on cannabinoid-based therapies targeting a range of medical conditions and disorders. Under the direction of Chief Science Officer Dr. Yehuda Baruch, former director of Israel’s Ministry of Health Medical Management Division, the company is developing a cannabinoid-based topical cream formulation that has shown significant reduction of a variety of inflammation markers directly associated with psoriasis.

“As soon as we announced the efficacy results of our pre-clinical psoriasis treatment, OWC has continued to receive active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary, and more, that adopted or are about to adopt MMJ bills,” said Mr. Mordechai Begnitz, OWC Pharmaceutical research Corp. Chairman & CEO. “We are currently in negotiations for scientific and marketing cooperation agreements.”

The company filed a U.S. patent application on June 27, 2017 for its active cannabinoid topical cream targeting psoriasis and similar medical conditions. Following the patent filing, the company announced its topical cream as “market ready”. Shortly after, the company expanded its intellectual property portfolio with a European patent in a bid to open the future products to global markets. A partnership with Germany’s mediq Innovation Partners aims to commercialize these claims by bringing a product to market in Europe over the coming months. Investors may want to keep an eye on the stock as the company gears up to commercialize the skin cream.

What is Psoriasis?

Psoriasis is an autoimmune disease that could pass down genetically, characterized by patches of red, itchy, and scaly skin. While nearly three-quarters of cases can be managed with topical treatments, there are no cures for the condition that also might be associated with increased risk of arthritis, lymphomas, cardiovascular disease, Crohn’s disease, and depression. The most commonly affected age group is 50 to 70 years olds, which means that the prevalence of the condition could increase as the global population ages.

The global psoriasis treatment market reached $7 billion in 2016, according to Market Research Future, which anticipates a 7.3% compound annual growth rate to $10.68 billion by 2022. Many large companies, such as Johnson & Johnson (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE), are involved in the market, but smaller companies may offer investors greater upside potential. These companies are generally divided into those targeting effective treatment options and those looking to cure the condition on a deeper level.

Cannabinoid Potential

Researchers have been intensifying their study of cannabinoids as the federal government relaxes regulations surrounding the drug. According to a recent study published by the NIH, cannabinoids could play an important role in the suppression of psoriasis via its anti-proliferation and anti-inflammatory properties. A separate study conducted at the University of Colorado found that cannabinoids, via their anti-proliferative and/or anti-inflammatory properties, may be effective against psoriasis, eczema, inflammatory skin disease, dermatitis, and even skin cancer in some cases.

Cannabinoid skin creams are widely available online, but the safety and efficacy of these products haven’t been studied in detail. Many doctors and dermatologists require these studies before recommending the products to patients to treat psoriasis. The good news is that some companies like OWC Pharma have begun studying cannabinoids across several medical indications, including psoriasis and other skin conditions. These studies could pave the way toward robust pharmaceutical products that have the potential to make a real difference for patients. 

Looking Ahead

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) represents a compelling investment opportunity within the burgeoning cannabis industry. With favorable pre-clinical results in hand, the company is well positioned as it advances clinical trials for its psoriasis skin cream. The multi-billion dollar market is ripe for innovation with no known cure, and cannabinoids have demonstrated the potential to reduce inflammation and skin proliferation. The company also continues to build up an enviable patent portfolio in the space.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading